Outlook Therapeutics, Inc.

The US Food and Drug Administration maintained a high rate of complete response letter actions for novel agent applications in 2024, but recent history suggests that many of the 16 CRL recipients will

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve its ONS-5010 bevacizumab candidate for wet age-related macular degeneration (AMD) despite the Phase III

Outlook Therapeutics is remaining hopeful that the US Food and Drug Administration will approve ONS-5010 for wet age-related macular degeneration (AMD) despite the Phase III NORSE EIGHT study not meet